#ariba_ref_name	ref_name	gene	var_only	flag	reads	cluster	ref_len	ref_base_assembled	pc_ident	ctg	ctg_len	ctg_cov	known_var	var_type	var_seq_type	known_var_change	has_known_var	ref_ctg_change	ref_ctg_effect	ref_start	ref_end	ref_nt	ctg_start	ctg_end	ctg_nt	smtls_total_depth	smtls_nts	smtls_nts_depth	var_description	free_text
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	531	12898	16S	1529	1529	99.87	16S.l15.c4.ctg.1	2200	583.8	0	.	n	.	0	A662G	SNP	662	662	A	1036	1036	G	792	G,A	719,1	.	.
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	531	12898	16S	1529	1529	99.87	16S.l15.c4.ctg.1	2200	583.8	0	.	n	.	0	C1450T	SNP	1450	1450	C	1824	1824	T	761	T,C	691,1	.	.
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	531	12898	16S	1529	1529	99.87	16S.l15.c4.ctg.1	2200	583.8	1	SNP	n	C1184T	0	.	.	1184	1184	C	1558	1558	C	758	C	700	16S.rDNA_WHO_F_01361c:0:1:C1184T:16S.1184T:E coli C1192T. Resistance to Spectinomycin	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	23480	23S	2890	2890	99.93	23S.l15.c17.ctg.1	3630	645.2	0	.	n	.	0	G1337A	SNP	1337	1337	G	1668	1668	A	841	A	768	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	23480	23S	2890	2890	99.93	23S.l15.c17.ctg.1	3630	645.2	0	.	n	.	0	T1971C	SNP	1971	1971	T	2302	2302	C	767	C,T	696,2	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	23480	23S	2890	2890	99.93	23S.l15.c17.ctg.1	3630	645.2	1	SNP	n	A2045G	0	.	.	2045	2045	A	2376	2376	A	744	A	689	23S.rDNA_WHO_F_01358c:0:1:A2045G:23S.2045G:E coli A2059G. High-level resistance to Azithromycin	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	23480	23S	2890	2890	99.93	23S.l15.c17.ctg.1	3630	645.2	1	SNP	n	C2597T	0	.	.	2597	2597	C	2928	2928	C	703	C	645	23S.rDNA_WHO_F_01358c:0:1:C2597T:23S.2597T :E coli C2611T. Low-level resistance to Azithromycin	.
blaTEM.WHO_M_pConjugative_00003	blaTEM.WHO_M_pConjugative_00003	1	0	16	12	blaTEM	861	199	100.0	blaTEM.l15.c4.ctg.1	199	2.5	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	Betalactam resistance
folP.WHO_F_01537c	folP.WHO_F_01537c	1	1	539	1886	folP	852	852	99.88	folP.l15.c4.ctg.1	1440	130.6	0	.	p	.	0	A204V	NONSYN	610	612	GCA	894	896	GTA	158;160;159	G;T;A	145;146;147	.	.
folP.WHO_F_01537c	folP.WHO_F_01537c	1	1	539	1886	folP	852	852	99.88	folP.l15.c4.ctg.1	1440	130.6	1	SNP	p	R228S	0	.	.	682	684	CGC	966	968	CGC	168;168;168	C,A;G;C	156,1;157;158	folP.WHO_F_01537c:1:1:R228S:folP.228S:Resistance to sulphonamides	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	27	5682	gyrA	2751	2751	99.96	gyrA.l6.c4.ctg.1	3196	176.6	1	SNP	p	S91F	0	.	.	271	273	TCC	507	509	TCC	206;203;204	T;C,A;C	187;185,1;187	gyrA.WHO_F_00668c:1:1:S91F:gyrA.91F:Resistance to fluoroquinolones	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	27	5682	gyrA	2751	2751	99.96	gyrA.l6.c4.ctg.1	3196	176.6	1	SNP	p	D95G	0	.	.	283	285	GAC	519	521	GAC	199;198;200	G;A;C	181;174;179	gyrA.WHO_F_00668c:1:1:D95G:gyrA.95G:Resistance to fluoroquinolones	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	27	5682	gyrA	2751	2751	99.96	gyrA.l6.c4.ctg.1	3196	176.6	1	SNP	p	D95N	0	.	.	283	285	GAC	519	521	GAC	199;198;200	G;A;C	181;174;179	gyrA.WHO_F_00668c:1:1:D95N:gyrA.95N:Resistance to fluoroquinolones	.
mtrR.WHO_L_00489c	mtrR.WHO_L_00489c	1	1	531	1462	mtrR	633	633	99.68	mtrR.l6.c30.ctg.1	1361	107.0	0	.	p	.	0	N71fs	FSHIFT	211	211	A	594	594	A	200	A	186	.	.
mtrR_promoter.WHO_F	mtrR_promoter.WHO_F	0	0	19	806	mtrR_promoter	250	250	100.0	mtrR_promoter.l6.c30.ctg.1	972	82.4	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
parC.WHO_G_00206c	parC.WHO_G_00206c	1	1	539	4856	parC	2304	2304	99.78	parC.l6.c4.ctg.1	2935	164.8	0	.	p	.	0	G459S	NONSYN	1375	1377	GGT	1765	1767	AGT	207;210;212	A,T;G;T	187,1;183;183	.	.
parC.WHO_G_00206c	parC.WHO_G_00206c	1	1	539	4856	parC	2304	2304	99.78	parC.l6.c4.ctg.1	2935	164.8	1	SNP	p	D86N	0	.	.	256	258	GAC	646	648	GAC	190;189;192	G;A;C	173;166;177	parC.WHO_G_00206c:1:1:D86N:parC.86N:Resistance to fluoroquinolones	.
parC.WHO_G_00206c	parC.WHO_G_00206c	1	1	539	4856	parC	2304	2304	99.78	parC.l6.c4.ctg.1	2935	164.8	1	SNP	p	S87W	0	.	.	259	261	AGT	649	651	AGT	194;194;194	A;G;T	177;179;174	parC.WHO_G_00206c:1:1:S87W:parC.87W:Resistance to fluoroquinolones	.
parC.WHO_G_00206c	parC.WHO_G_00206c	1	1	539	4856	parC	2304	2304	99.78	parC.l6.c4.ctg.1	2935	164.8	1	SNP	p	S87I	0	.	.	259	261	AGT	649	651	AGT	194;194;194	A;G;T	177;179;174	parC.WHO_G_00206c:1:1:S87I:parC.87I:Resistance to fluoroquinolones	.
parC.WHO_G_00206c	parC.WHO_G_00206c	1	1	539	4856	parC	2304	2304	99.78	parC.l6.c4.ctg.1	2935	164.8	1	SNP	p	S87R	0	.	.	259	261	AGT	649	651	AGT	194;194;194	A;G;T	177;179;174	parC.WHO_G_00206c:1:1:S87R:parC.87R:Resistance to fluoroquinolones	.
parC.WHO_G_00206c	parC.WHO_G_00206c	1	1	539	4856	parC	2304	2304	99.78	parC.l6.c4.ctg.1	2935	164.8	1	SNP	p	S88P	0	.	.	262	264	TCC	652	654	TCC	192;193;195	T;C;C	174;177;178	parC.WHO_G_00206c:1:1:S88P:parC.88P:Resistance to fluoroquinolones	.
parE.WHO_F_01528c	parE.WHO_F_01528c	1	1	27	4202	parE	1986	1986	99.95	parE.l15.c4.ctg.1	2685	155.9	1	SNP	p	G410V	0	.	.	1228	1230	GGC	1579	1581	GGC	236;232;232	G;G;C	217;211;209	parE.WHO_F_01528c:1:1:G410V:parE.410V:Resistance to fluoroquinolones	.
penA.22.001	penA.22.001	1	1	27	3682	penA	1752	1752	100.0	penA.l15.c4.ctg.1	2415	152.0	1	SNP	p	A311V	0	.	.	931	933	GCA	1308	1310	GCA	171;171;171	G;C,A;A	155;157,1;160	penA.22.001:1:1:A311V:penA.311V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.22.001	penA.22.001	1	1	27	3682	penA	1752	1752	100.0	penA.l15.c4.ctg.1	2415	152.0	1	SNP	p	I312M	0	.	.	934	936	ATC	1311	1313	ATC	169;169;170	A;T;C	158;156;158	penA.22.001:1:1:I312M:penA.312M:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.22.001	penA.22.001	1	1	27	3682	penA	1752	1752	100.0	penA.l15.c4.ctg.1	2415	152.0	1	SNP	p	V316P	0	.	.	946	948	GTG	1323	1325	GTG	172;172;175	G;T;G	158;158;162	penA.22.001:1:1:V316P:penA.316P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.22.001	penA.22.001	1	1	27	3682	penA	1752	1752	100.0	penA.l15.c4.ctg.1	2415	152.0	1	SNP	p	V316T	0	.	.	946	948	GTG	1323	1325	GTG	172;172;175	G;T;G	158;158;162	penA.22.001:1:1:V316T:penA.316T:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.22.001	penA.22.001	1	1	27	3682	penA	1752	1752	100.0	penA.l15.c4.ctg.1	2415	152.0	1	SNP	p	T484S	0	.	.	1450	1452	ACC	1827	1829	ACC	198;198;198	A;C;C	173;176;176	penA.22.001:1:1:T484S:penA.483S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.22.001	penA.22.001	1	1	27	3682	penA	1752	1752	100.0	penA.l15.c4.ctg.1	2415	152.0	1	SNP	p	A502P	0	.	.	1504	1506	GCG	1881	1883	GCG	184;188;188	G;C;G	163;156;161	penA.22.001:1:1:A502P:penA.501P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.22.001	penA.22.001	1	1	27	3682	penA	1752	1752	100.0	penA.l15.c4.ctg.1	2415	152.0	1	SNP	p	A502V	0	.	.	1504	1506	GCG	1881	1883	GCG	184;188;188	G;C;G	163;156;161	penA.22.001:1:1:A502V:penA.501V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.22.001	penA.22.001	1	1	27	3682	penA	1752	1752	100.0	penA.l15.c4.ctg.1	2415	152.0	1	SNP	p	G543S	0	.	.	1627	1629	GGT	2004	2006	GGT	159;155;156	G;G;T	147;143;144	penA.22.001:1:1:G543S:penA.542S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.22.001	penA.22.001	1	1	27	3682	penA	1752	1752	100.0	penA.l15.c4.ctg.1	2415	152.0	1	SNP	p	G546S	0	.	.	1636	1638	GGC	2013	2015	GGC	149;151;147	G;G;C	135;135;130	penA.22.001:1:1:G546S:penA.545S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.22.001	penA.22.001	1	1	27	3682	penA	1752	1752	100.0	penA.l15.c4.ctg.1	2415	152.0	1	SNP	p	P552S	0	.	.	1654	1656	CCG	2031	2033	CCG	150;150;153	C;C;G	110;121;120	penA.22.001:1:1:P552S:penA.551S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
ponA.WHO_G_00106	ponA.WHO_G_00106	1	1	27	5034	ponA	2397	2397	99.96	ponA.l15.c4.ctg.1	3069	163.6	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
porA.NCCP11945	porA.NCCP11945	1	0	531	2232	porA	1146	1146	99.56	porA.l15.c4.ctg.1	1852	120.0	0	.	p	.	0	S22G	NONSYN	64	66	AGC	363	365	GGC	154;153;157	G,A;G,A;C	139,1;134,1;139	.	.
porA.NCCP11945	porA.NCCP11945	1	0	531	2232	porA	1146	1146	99.56	porA.l15.c4.ctg.1	1852	120.0	0	.	p	.	0	M83fs	FSHIFT	247	247	A	545	545	C	163	C	147	.	.
porB1a.WHO_G_02195c	porB1a.WHO_G_02195c	1	0	528	162	porB1a	984	271	91.14	porB1a.l15.c30.ctg.2	349	11.5	0	.	p	.	0	S271T	NONSYN	811	813	TCG	129	131	ACT	23;20;20	A;C;T	19;17;17	.	.
porB1a.WHO_G_02195c	porB1a.WHO_G_02195c	1	0	528	162	porB1a	984	271	91.14	porB1a.l15.c30.ctg.2	349	11.5	0	.	p	.	0	Y273D	NONSYN	817	819	TAT	135	137	GAT	11;6;4	G;A;T	8;5;4	.	.
porB1a.WHO_G_02195c	porB1a.WHO_G_02195c	1	0	528	162	porB1a	984	271	91.14	porB1a.l15.c30.ctg.2	349	11.5	0	.	p	.	0	D274S	NONSYN	820	822	GAT	138	140	AGT	4;4;4	A;G;T	4;4;4	.	.
porB1a.WHO_G_02195c	porB1a.WHO_G_02195c	1	0	528	162	porB1a	984	271	91.14	porB1a.l15.c30.ctg.2	349	11.5	0	.	p	.	0	N277H	NONSYN	829	831	AAC	147	149	CAC	6;6;6	C;A;C	6;6;6	.	.
porB1a.WHO_G_02195c	porB1a.WHO_G_02195c	1	0	528	162	porB1a	984	271	91.14	porB1a.l15.c30.ctg.2	349	11.5	0	.	p	.	0	R307E	NONSYN	919	921	AGA	237	239	GAA	5;5;5	G;A;A	5;5;5	.	.
porB1a.WHO_G_02195c	porB1a.WHO_G_02195c	1	0	528	162	porB1a	984	271	91.14	porB1a.l15.c30.ctg.2	349	11.5	0	.	p	.	0	T311A	NONSYN	931	933	ACA	249	251	GCA	3;4;4	G;C;A	3;4;4	.	.
porB1a.WHO_G_02195c	porB1a.WHO_G_02195c	1	0	528	162	porB1a	984	271	91.14	porB1a.l15.c30.ctg.2	349	11.5	0	.	p	.	0	E312D	NONSYN	934	936	GAA	252	254	GAC	4;4;4	G;A;C	4;4;4	.	.
porB1a.WHO_G_02195c	porB1a.WHO_G_02195c	1	0	528	162	porB1a	984	271	91.14	porB1a.l15.c30.ctg.2	349	11.5	0	.	p	.	0	F314I	NONSYN	940	942	TTC	258	260	ATC	4;4;4	A;T;C	4;4;4	.	.
porB1a.WHO_G_02195c	porB1a.WHO_G_02195c	1	0	528	162	porB1a	984	271	91.14	porB1a.l15.c30.ctg.2	349	11.5	0	.	p	.	0	A316S	NONSYN	946	948	GCG	264	266	TCG	4;3;3	T;C;G	4;3;3	.	.
porB1a.WHO_G_02195c	porB1a.WHO_G_02195c	1	0	528	162	porB1a	984	271	91.14	porB1a.l15.c30.ctg.2	349	11.5	0	.	p	.	0	V318A	NONSYN	952	954	GTC	270	272	GCC	3;2;2	G;C;C	3;2;2	.	.
porB1a.WHO_G_02195c	porB1a.WHO_G_02195c	1	0	528	162	porB1a	984	271	91.14	porB1a.l15.c30.ctg.2	349	11.5	0	.	p	.	0	G319S	NONSYN	955	957	GGC	273	275	AGC	2;2;2	A;G;C	2;2;2	.	.
porB1a.WHO_G_02195c	porB1a.WHO_G_02195c	1	0	528	162	porB1a	984	271	91.14	porB1a.l15.c30.ctg.2	349	11.5	0	.	p	.	0	G320A	NONSYN	958	960	GGT	276	278	GCC	2;3;3	G;C;C	2;2;2	.	.
porB1a.WHO_G_02195c	porB1a.WHO_G_02195c	1	0	528	162	porB1a	984	271	91.14	porB1a.l15.c30.ctg.2	349	11.5	0	.	p	.	0	G322V	NONSYN	964	966	GGT	282	284	GTT	4;4;4	G;T;T	2;4;4	.	.
porB1b.WHO_P_02204c	porB1b.WHO_P_02204c	1	1	539	2370	porB1b	1047	1047	98.95	porB1b.l15.c17.ctg.1	1491	158.1	0	.	p	.	0	Y34H	NONSYN	100	102	TAC	400	402	CAC	199;200;200	C;A;C	177;180;181	.	.
porB1b.WHO_P_02204c	porB1b.WHO_P_02204c	1	1	539	2370	porB1b	1047	1047	98.95	porB1b.l15.c17.ctg.1	1491	158.1	0	.	p	.	0	K143Q	NONSYN	427	429	AAA	727	729	CAA	199;198;203	C;A;A	184;181;187	.	.
porB1b.WHO_P_02204c	porB1b.WHO_P_02204c	1	1	539	2370	porB1b	1047	1047	98.95	porB1b.l15.c17.ctg.1	1491	158.1	0	.	p	.	0	E212S	NONSYN	634	636	GAA	934	936	AGT	182;182;182	A;G;T	169;169;162	.	.
porB1b.WHO_P_02204c	porB1b.WHO_P_02204c	1	1	539	2370	porB1b	1047	1047	98.95	porB1b.l15.c17.ctg.1	1491	158.1	0	.	p	.	0	H213D	NONSYN	637	639	CAT	937	939	GAT	179;181;181	G;A;T	165;165;166	.	.
porB1b.WHO_P_02204c	porB1b.WHO_P_02204c	1	1	539	2370	porB1b	1047	1047	98.95	porB1b.l15.c17.ctg.1	1491	158.1	0	.	p	.	0	V215D	NONSYN	643	645	GTT	943	945	GAT	182;184;183	G;A,C;T	169;167,1;170	.	.
porB1b.WHO_P_02204c	porB1b.WHO_P_02204c	1	1	539	2370	porB1b	1047	1047	98.95	porB1b.l15.c17.ctg.1	1491	158.1	0	.	p	.	0	I218M	NONSYN	652	654	ATC	952	954	ATG	187;189;188	A;T;G,C	175;179;174,1	.	.
porB1b.WHO_P_02204c	porB1b.WHO_P_02204c	1	1	539	2370	porB1b	1047	1047	98.95	porB1b.l15.c17.ctg.1	1491	158.1	1	SNP	p	G120K	0	.	.	358	360	GGC	658	660	GGC	201;198;197	G,A;G,A;C,G	191,1;186,1;186,1	porB1b.WHO_P_02204c:1:1:G120K:porB1b.120K:G101K. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
rpoB.WHO_F_02153c	rpoB.WHO_F_02153c	1	1	27	8798	rpoB	4179	4179	100.0	rpoB.l15.c30.ctg.1	4799	182.9	1	SNP	p	H553N	0	.	.	1657	1659	CAT	1938	1940	CAT	198;199;196	C;A,T;T	189;189,1;189	rpoB.WHO_F_02153c:1:1:H553N:rpoB.553N:H552N. High-level resistance to Rifampicin	.
rpsJ.WHO_Y_02241	rpsJ.WHO_Y_02241	1	1	27	902	rpsJ	312	312	100.0	rpsJ.l15.c4.ctg.1	1112	80.8	1	SNP	p	V57M	1	.	.	169	171	ATG	509	511	ATG	194;192;194	A;T;G	180;175;178	rpsJ.WHO_Y_02241:1:1:V57M:rpsJ.57M:Chromosomally-mediated resistance to tetracyclines	.
